Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.

  title={Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.},
  author={Kyle A Totaro and Dominik Barthelme and Peter T. Simpson and Robert T. Sauer and Jason K. Sello},
  journal={Bioorganic \& medicinal chemistry},
  volume={23 18},
8 Citations

Figures and Tables from this paper

Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors
The following review discusses the efforts made in the field to isolate and identify natural products as inhibitors of the proteasome and some of the modifications made to natural products in order to discover more potent and selective inhibitors for potential disease treatment.
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
Selective inhibitors of the Mtb 20S were designed and synthesized on the bases of both its unique substrate preferences and the structures of substrate-mimicking covalent inhibitors of eukaryotic proteasomes called syringolins and do not inhibit the growth of human cell lines in vitro and thus may be starting points for tuberculosis drug development.
Design, Synthesis and Biological Evaluation of a Structurally Simplified Syringolin A Analogues.
A structurally simplified syringolin A analogue 4 is designed and synthesized, which could have a switched hydrogen bonding interaction with the β5 subunit of 20S proteasome and shows cytotoxicity against a range of human cancer cells at submicromolar level.
Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Design, Synthesis, and Biological Activity of Isosyringolin A.
It was revealed that isosyringolin A exhibited proteasome-inhibitory activity comparable to that of syringol A and that its derivatization leads to great enhancement in its proteasomesome inhibitory activity as well as its cytotoxicity against human myeloma cells.
Synthesis of macrocyclic α-ketoamide as a selective and reversible immunoproteasome inhibitor
The design, synthesis, and evaluation of a new immunoproteasome inhibitor that feature a macrocyclic ring containing an internal α-ketoamide warhead and shows essentially no inhibition of constitutive proteasome subunits is reported.
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death*
The results suggest that TIR-199 is a potent new proteasome inhibitor with promise for further development into a clinical drug for the treatment of multiple myeloma and other forms of cancer.


Total synthesis of syringolin A and improvement of its biological activity.
The development process for syringolin A analogues having improved proteasome inhibitory and antitumor activity is described, and these biological properties are comparable to those of bortezomib, a clinically used first-line proteasomesome inhibitor.
Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition
The total synthesis of syringolin A and B was described, which together with enzyme kinetic and structural studies, allowed us to elucidate the structural determinants underlying the proteasomal subsite selectivity and binding affinity of syrbactins.
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma
The newly designed proteasome inhibitor TIR-203 is more potent than the natural product SylA and strongly inhibits the cell viability and proteasomal activity of MM and NB cells.
Convergent Synthesis and Biological Evaluation of Syringolin A and Derivatives as Eukaryotic 20S Proteasome Inhibitors
A convergent synthesis of SylA was developed and consists of the synthesis of a fully functionalized macrocycle, which is subsequently coupled with a urea moiety, revealing PEGylated SylA derivatives as the most potent proteasome inhibitors.
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
This review highlights the important role of the structural elucidation of the various unique binding mechanisms of these compounds that have been optimized throughout evolution to target the proteasome in finding potential drugs with reduced off-target activities.
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
A novel pharmacodynamic assay has shown that bortezomib–mediated proteasome blockade is dose-dependent and reversible, and phase II trials have been initiated for both solid and hematological malignancies.
The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.
The preparation of a Syringolin A/Glidobactin A hybrid (SylA-GlbA) consisting of a SylA macrocycle connected to the GlbA side chain and its potent proteasome targeting of all three proteasomal